Clinical Trial Detail

NCT ID NCT03173560
Title Trial to Assess Safety and Efficacy of Lenvatinib in Combination With Everolimus in Participants With Renal Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Eisai Inc.
Indications

clear cell renal cell carcinoma

Therapies

Everolimus + Lenvatinib

Age Groups: adult senior

No variant requirements are available.